Secukinumab’s time to psoriasis response on patient-reported psoriasis symptoms (ERASURE study)
Background: Secukinumab (AIN457), a fully human anti–interleukin-17A monoclonal antibody, was evaluated in a phase 3 clinical study at week 12 (vs. placebo) for efficacy and safety in subjects with moderate to severe plaque psoriasis. Time to symptom response was evaluated using the Psoriasis Symptom Diary (PSD), which measures psoriasis-related characteristics subjects have reported as important and relevant to their disease and treatment.
Citation
Gottlieb, A., Gnanasakthy, A., Strober, B., Zhang, J., & Tran, MH. (2014). Secukinumab’s time to psoriasis response on patient-reported psoriasis symptoms (ERASURE study). Journal of the American Academy of Dermatology, 70(5, Suppl. 1), AB189. DOI: 10.1016/j.jaad.2014.01.782
